Please see below for links to the on-going CAELUM CARES CAEL-101 clinical trials:

Phase 2: A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis (ClinicalTrials.gov Identifier: NCT04304144)

Phase 3: A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients with Mayo Stage IIIa AL Amyloidosis (ClinicalTrials.gov Identifier: NCT04512235)

Phase 3: A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (ClinicalTrials.gov Identifier: NCT04504825)